ArticleFrontiers in psychology2026
Turkish adaptation study of the Metacognition Assessment Scale-Abbreviated in psychotic disorders.
Article in Frontiers in psychology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Metacognition refers to the ability to recognize one's own and others' feelings and thoughts and to utilize this information to develop and understanding of oneself and others. Given that metacognitive deficits are considered a key treatment target in schizophrenia spectrum disorder, the availability of reliable tools to measure these skills is essential. As an interviewer-rated scale, the Metacognition Assessment Scale-Abbreviated (MAS-A) offers advantages over self-report scales in assessing metacognitive capacity. This study aims to evaluate the validity and reliability of the Turkish version of MAS-A for clinical assessment of metacognitve skills. Methods: MAS-A was administered to 70 psychotic patients. Interrater reliability and compliance were assessed using intraclass correlation coefficients. A two-way mixed model was employed for intraclass correlation coefficients analyses. Participants were also administered: Metacognitions Questionnare-30, Beck Cognitive Insight Scale, Reading the Mind in the Eyes Test, Facial Emotion Identification and Discrimination Tests for convergent validity analysis; Positive and Negative Syndrome Scale for assessing psychopathology; Global Assessment of Functioning Scale for assessing functionality. These scales, along with the related subscales of MAS-A, were examined through correlation and hierarchical regression analyses. Results: Intraclass correlation coefficients for MAS-A total and subscale scores ranged between 0.877 to 0.968 ( Conclusion: The Turkish form of MAS-A has been found to be valid and reliable for patients with psychotic disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.